122853-76-3

Basic information

• Product Name: 3-(4-fluorobenzoyl)-4-pyridine carboxylic acid
• Synonyms: 3-(4-fluorobenzoyl)-4-pyridine carboxylic acid
• CAS NO: 122853-76-3
• Molecular Weight: 245.21
• Mol File: 122853-76-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-(4-fluorobenzoyl)-4-pyridine carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-fluorobenzoyl)-4-pyridine carboxylic acid(122853-76-3)
• EPA Substance Registry System: 3-(4-fluorobenzoyl)-4-pyridine carboxylic acid(122853-76-3)

Safety Data

• Hazardous Substances Data: 122853-76-3(Hazardous Substances Data)

Upstream product

• 462-06-6 fluorobenzene 
• 4664-08-8 cinchomeronic anhydride 
• 24202-74-2 4-(methoxycarbonyl)nicotinic acid 

Downstream Products

• 168541-26-2 N-[3,5-Bis(trifluoromethyl)benzyl]-4-(4-fluorophenyl)-1,2-dihydro-N, 2-dimethyl-1-oxo-3-pyrido[4,3-c]pyridine carboxamide 
• 168542-07-2 {[3-(4-Fluoro-benzoyl)-pyridine-4-carbonyl]-methyl-amino}-acetic acid ethyl ester 
• 168542-11-8 4-(4-fluorophenyl)-1,2-dihydro-2-methyl-1-oxo-3-pyrido[4,3-c]pyridinecarboxylic acid ethyl ester 
• 168542-06-1 4-(4-fluorophenyl)-1,2-dihydro-2-methyl-1-oxo-3-pyrido[4,3-c]pyridine carboxylic acid 

Relevant articles and documents

Potent NK1 receptor antagonists: synthesis and antagonistic activity of various heterocycles with an N-[3,5-bis(trifluoromethyl)benzyl]-N-methylcarbamoyl substituent.

Various N-[3,5-bis(trifluoromethyl)benzyl]-N-methylcarbamoyl heterocycles (1, 2 and 3) modified at rings A and B in the isoquinolone (1a) and pyrido[3,4-b]pyridine (2a) nuclei were prepared and evaluated for NK1 receptor antagonistic activities. The structure-activity relationship studies on this series, along with conformational analysis, showed that (i) for ring A, 6-membered heterocycles are preferable to 5-membered heterocycles (a ca. 300-fold difference in potency), (ii) the 6-membered ring seems to function as an anchor by fixing the pendant phenyl group in a desirable orientation for receptor binding, and (iii) since compounds with aromatic rings (2) and those with aliphatic rings (3) as ring B both show good potency, this ring does not seem to be essential for receptor recognition. Among the compounds synthesized, the tetrahydropyridine derivatives 3a, 3b and 3f exhibited excellent inhibitory effects both in vitro and in vivo, with potent activity upon oral administration (ED50 = 0.20-0.27 mg/kg) (capsaicin-induced plasma extravasation in guinea pig trachea).

Imidazolylphenyl and 1,2,4-triazolylphenyl benzopyridazinone and pyridopyridazinone compounds and their use for increasing cardiatonic contractility

This invention relates to imidazolylphenyl and 1,2,4-triazolylphenyl benzopyridazinone and pyridopyridazinone compounds of the formula STR1 wherein A is CH or N and not more than one of W, X, Y and Z is a N atom which possess valuable pharmaceutical preparations, e.g., increasing cardiotonic contractility. Uses of said compounds including methods for increasing cardiac contractility and in the treatment of congestive heart failure, pharmaceutical compositions including the same and methods for the preparation thereof.